Combined arsenic trioxide and all‐trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide
Open Access
- 25 March 2002
- journal article
- case report
- Published by Wiley in British Journal of Haematology
- Vol. 117 (1) , 130-132
Abstract
Summary. The optimal treatment of acute promyelocytic leukaemia (APL) recurring from relapses successfully treated using arsenic trioxide (As2O3) is undefined. Three APL patients relapsing from As2O3‐induced remission were studied. Re‐treatment with As2O3 failed in one patient in third relapse, and resulted in morphological but not molecular remission in another patient. Combination therapy with As2O3 and all‐trans retinoic acid (ATRA), however, resulted in morphological and molecular remission in all three cases, with a follow‐up time ranging from 6 to 16 months. Our results suggest a synergistic therapeutic effect between As2O3 and ATRA in APL in advanced relapse.Keywords
This publication has 10 references indexed in Scilit:
- Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: Clinicopathological and molecular features of a pilot studyAmerican Journal of Hematology, 2001
- Unusual Manifestations of Acute LeukemiaJournal of Clinical Oncology, 2000
- Retinoic acid (RA) and As 2 O 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteinsProceedings of the National Academy of Sciences, 2000
- Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia PatientsBlood, 1999
- Retinoic Acid and Arsenic Synergize to Eradicate Leukemic Cells in a Mouse Model of Acute Promyelocytic LeukemiaJournal of Experimental Medicine, 1999
- Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic TrioxideNew England Journal of Medicine, 1998
- Combined Arsenic and Retinoic Acid Treatment Enhances Differentiation and Apoptosis in Arsenic-Resistant NB4 CellsBlood, 1998
- Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed PatientsBlood, 1997
- Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemiaBlood, 1995
- Trisomy 8 in acute promyelocytic leukaemia: an interphase study by fluorescence in situ hybridizationBritish Journal of Haematology, 1995